- Home
- DVA vs ELAN Comparison
DVA vs ELAN Comparison
Compare DVA & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DVA | ELAN |
|---|---|---|
| Founded | 1994 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 12.4B |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DVA | ELAN |
|---|---|---|
| Price | $180.67 | $24.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $156.75 | $27.89 |
| AVG Volume (30 Days) | 845.0K | ★ 4.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.86 | 0.22 |
| Revenue | ★ $13,643,069,000.00 | $4,715,000,000.00 |
| Revenue This Year | $3.85 | $8.21 |
| Revenue Next Year | $3.07 | $5.31 |
| P/E Ratio | ★ $27.51 | $119.27 |
| Revenue Growth | ★ 6.46 | 6.22 |
| 52 Week Low | $101.00 | $16.15 |
| 52 Week High | $247.49 | $27.98 |
Technical Indicators
Market Signals| Indicator | DVA | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 22.50 | 42.57 |
| Support Level | $145.58 | $23.94 |
| Resistance Level | $202.63 | $25.67 |
| Average True Range (ATR) | 7.54 | 0.99 |
| MACD | -6.40 | -0.12 |
| Stochastic Oscillator | 4.10 | 4.38 |
Price Performance
Historical ComparisonAbout DVA DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.